An evolutionary approach to restoring health
AOBiome Therapeutics is a clinical-stage therapeutics company addressing a broad range of inflammatory conditions by harnessing a single strain of class defining
Ammonia Oxidizing Bacteria (AOB).
The Bio-inflammation Company
Transforming Human Health Through The Restoration Of Ammonia-Oxidizing BacteriaAOBiome currently has multiple
Phase 2 clinical programs ongoing
AOBiome currently has ongoing Phase 2 clinical programs in hypertension, acne, allergic rhinitis, migraine, eczema and rosacea.
Committed to transforming & improving human health
We believe that the restoration of the symbiotic relationship between bacteria and humans
will have a profound impact on human health.
In the News
March 6, 2019
· Cambridge, MA
AOBiome Doses First Patient in Phase 1b Clinical Trial of B244 for the Treatment of Pediatric Atopic Dermatitis
January 2, 2019
· Cambridge, MA
AOBiome Therapeutics Expands Intellectual Property Estate with Issuance of U.S. Patent for Use of Ammonia Oxidizing Bacteria (AOB) for the Treatment of Eczema
December 18, 2018
· Cambridge, MA
AOBiome Therapeutics Announces Appointment of Dr. Judith Ng Cashin as Chief Medical Officer